DPP4 inhibitors are currently being used as part of the medical management of T2DM in humans, as they improve glycaemic control through increasing GLP-1 concentrations, thus stimulating pancreatic insulin secretion, inhibiting glucagon release and reducing appetite [46]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.